10x Genomics, Inc.

For the period ended Sep 30, 2026. Filed Nov 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 6, 2026

TXG$65.05+9.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)

	Three Months EndedSeptember 30,		Nine Months EndedSeptember 30,
	2026	2025	2026	2025
Products and services revenue	$150,210	$148,019	$449,200	$430,999
License and royalty revenue	457	983	3,346	45,794
Revenue	150,667	149,002	452,546	476,793
Cost of products and services revenue	37,740	48,695	120,944	145,957
Gross profit	112,927	100,307	331,602	330,836
Operating expenses:
Research and development	52,929	57,194	166,567	182,663
Selling, general and administrative	76,055	75,355	221,093	239,517
Gain on settlement	—	—	(3,400)	(49,900)
Total operating expenses	128,984	132,549	384,260	372,280
Loss from operations	(16,057)	(32,242)	(52,658)	(41,444)
Other income (expense):
Interest income	5,018	5,199	14,829	13,156
Interest expense	—	3	—	—
Other income (expense), net	(7,437)	(1,165)	(12,139)	3,574
Total other income (expense)	(2,419)	4,037	2,690	16,730
Loss before provision for income taxes	(18,476)	(28,205)	(49,968)	(24,714)
Provision for (benefit from) income taxes	949	(733)	858	2,578
Net loss	$(19,425)	$(27,472)	$(50,826)	$(27,292)
Net loss per share, basic and diluted	$(0.15)	$(0.22)	$(0.39)	$(0.22)
Weighted-average shares used to compute net loss per share, basic and diluted	130,805,838	125,502,291	129,570,736	123,965,205

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.